



PATENT
Attorney Docket No.: ADL-101
Customer No. 39,013

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re U.S. Patent Application of

Applicant: Cindy ORSER *et al.*

Application No.: 10/728,246

Filing Date: 4 December 2003

Group Art Unit: Not Yet Assigned

Examiner: Not Yet Assigned

Confirmation Number: 8108

Title: DETECTION OF CONFORMATIONALLY ALTERED PROTEINS AND PRIONS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97(b)

Sir:

Pursuant to 37 C.F.R. §§ 1.56 and 1.97(b), Applicants bring to the attention of the Examiner the documents listed on the attached Form PTO-1449. This Information Disclosure Statement is being filed before issuance of a first Office Action on the merits.

Additionally, Applicants would like to bring to the Examiner's attention the following co-pending U.S. patent applications, which the Examiner might find relates to similar subject matter:

U.S. Patent Application No. 11/030,300, filed 7 January 2005.

Copies of non-U.S. patent documents are attached.

Applicants respectfully request that the Examiner consider the documents listed on the attached Form PTO-1449 and indicate that they were considered by making appropriate notations on the attached Form PTO-1449.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each, any, or all of the listed documents are material or constitute prior art. If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute prior art under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the claimed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

Please grant any extensions of time required to enter this paper and charge any required fees to Deposit Account No. 502882.

Respectfully submitted,
Cindy ORSER *et al.*



Date: 28 October 2005

By: _____

Matthew T. Latimer
Reg. No. 44,204

MOAZZAM & LATIMER LLP
1474 North Point Village Center #320
Reston, VA 20194-1190
703-471-4856
matthew.latimer@moazzamlaw.com



INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101	Application No.: 10/728,246
Applicant: Cindy ORSER et al.	
Filing Date: 4 December 2003	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS


		Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	B1	Anantharamaiah, G.M., et al., "Studies of Synthetic Peptide Analogs of the Amphipathic Helix", <i>J. Biol. Chem.</i> 260 (18):10248-10255, 1985.
	B2	Anfinsen, C.B., "Principles that Govern the Folding of Protein Chains", <i>Science</i> 181 (4096):223-230, 1973.
	A1	Baba, M., et al., "Aggregation of α -Synuclein in Lewy Bodies of Sporadic Parkinson's Disease and Dementia with Lewy Bodies", <i>Am. J. Pathology</i> 152 (4):879-885, 1998.
	B3	Baker, D., "A surprising simplicity to protein folding", <i>Nature</i> 405 :39-42, 2000.
	A2	Booth, D.R., et al., "Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis", <i>Nature</i> 385 :787-793, 1997.
	A3	Carrell, R.W. et al., "Conformational Disease", <i>The Lancet</i> 350 :134-138, 1997.
	B4	Chiti, F., et al., "Designing conditions for <i>in vitro</i> formation of amyloid protofilaments and fibrils", <i>Proc. Natl. Acad. Sci. USA</i> 96 :3590-3594, 1999.
	B5	Daura, X., et al., "Reversible Peptide Folding in Solution by Molecular Dynamics Simulation", <i>J. Mol. Biol.</i> 280 :925-932, 1998.
	A4	Dobson, C.M., "Protein misfolding, evolution and disease", <i>TIBS</i> 24 :329-332, 1999.

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101	Application No.: 10/728,246
Applicant: Cindy ORSER et al.	
Filing Date: 4 December 2003	Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A5	Dobson, C.M., "The structural basis of protein folding and its links with human disease", <i>Phil. Trans. R. Soc. London B</i> 356:133-145, 2001.
	B6	Dobson, C.M. et al., "Kinetic studies of protein folding using NMR spectroscopy", <i>Nature Structural Biology Suppl.</i> 5:504-507, July 1998.
	A6	Epstein, F.H., "Molecular Basis Of The Neurodegenerative Disorders", <i>New. Eng. J. Med.</i> 340(25):1970-1980, 1999.
	B7	Isenman, D.E., et al., "The Structure and Function of Immunoglobulin Domains", <i>Proc. Natl. Acad. Sci. USA</i> 72(2):548-552, 1975.
	B8	Krawczak, M., et al., "Human Gene Mutation Database - A Biomedical Information and Research Resource", <i>Human Mutation</i> 15:45-51, 2000.
	A7	Lansbury, P.T., "Evolution of amyloid: What normal protein folding may tell us about fibrillogenesis and disease", <i>Proc. Natl. Acad. Sci. USA</i> 96:3342-3344, 1999.
	B9	Levy, E., et al., "Stroke In Icelandic Patients With Hereditary Amyloid Angiopathy Is Related To A Mutation In The Cystatin C Gene, An Inhibitor Of Cysteine Proteases", <i>J. Exp. Med.</i> 169:1771-1778, 1989.
	A8	Liao, Y-C.J., et al., "Human Prion Protein cDNA: Molecular Cloning, Chromosomal Mapping, and Biological Implications", <i>Science</i> 233:364-367, 1986.

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101

Application No.: 10/728,246

Applicant: Cindy ORSER et al.

OCT 28 2005

Filing Date: 4 December 2003

Group Art Unit: Not Yet Assigned

U.S. PATENT DOCUMENTS

Examiner Initial*		Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Sub Class	Translation Yes or No

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	A9	MacPhee, C.E., et al., "Chemical Dissection and Reassembly of Amyloid Fibrils Formed by a Peptide Fragment of Transthyretin", <i>J. Mol. Biol.</i> 297:1203-1215, 2000.
	B10	Matouschek, A., et al., "Mapping the transition state and pathway of protein folding by protein engineering", <i>Nature</i> 340:122-126, 1989.
	A10	Nguyen, J., et al., "Prion Protein Peptides Induce α -Helix to β -Sheet Conformational Transitions", <i>Biochemistry</i> 34:4186-4192, 1995.
	A11	Oesch, B., et al., "A Cellular Gene Encodes Scrapie PrP 27-30 Protein", <i>Cell</i> 40:735-746, 1985.
	A12	Perutz, M.F., "Glutamine repeats and neurodegenerative disease: molecular aspects", <i>TIBS</i> 24:58-63, 1999.
	A13	Prusiner, S.B., et al., "Prion Protein Biology", <i>Cell</i> 93:337-348, 1998.
	A14	Riordan, J.R., "Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA", <i>Science</i> 245:1066-1073, 1989.
	A15	Salmona, M., et al., "Molecular determinants of the physicochemical properties of a critical prion protein region comprising residues 106-126", <i>Biochemical Journal</i> 342:207-214, 1999.
	A16	Schatzl, H.M., "Prion Protein Gene Variation Among Primates", <i>J. Mol. Biol.</i> 245:362-374, 1995.

Examiner	Date Considered
----------	-----------------

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION

Atty. Docket No.: ADL-101	Application No.: 10/728,246					
Applicant: Cindy ORSER et al.						
Filing Date: 4 December 2003	Group Art Unit: Not Yet Assigned					
OCT 28 2005 U.S. PATENT DOCUMENTS						
Examiner Initial	Document Number	Date	Name	Class	Sub Class	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS						
		Document Number	Date	Country	Class	Sub Class
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
A17	Soto, C., "Protein misfolding and disease; protein refolding and therapy", <i>FEBS Letters</i> 498:204-207, 2001.					
B11	Speed, M.A., et al., "Polymerization Mechanism of Polypeptide Chain Aggregation", <i>Biotechnology and Bioengineering</i> 54(4):333-343, 1997.					
B12	Speed, M.A., et al., "Specific aggregation of partially folded polypeptide chains: The molecular basis of inclusion body composition", <i>Nature Biotechnology</i> 14:1283-1287, 1996.					
A18	Spillantini, M.G., " α -Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies", <i>Proc. Natl. Acad. Sci. USA</i> 95:6469-6473, 1998.					
A19	Spillantini, M.G., " α -Synuclein in Lewy bodies" <i>Nature</i> 388:839-840, 1997.					
A20	Stahl, N., et al., "Prions and prion proteins", <i>The FASEB Journal</i> 5:2799-2807, 1991.					
B13	Surewicz, W.K., et al., "Infrared spectroscopic evidence of conformational transitions of an atrial natriuretic peptide", <i>Proc. Natl. Acad. Sci. USA</i> 84:7028-7030, 1987.					
A21	Thomas, P.J., et al., "Defective protein folding as a basis of human disease", <i>TIBS</i> 20:456-459, 1995.					
A22	Westaway, D., et al., "Distinct Prion Proteins in Short and Long Scrapie Incubation Period Mice", <i>Cell</i> 51:651-662, 1987.					
A23	Prior, R., et al., "Selective binding of Soluble A β 1-40 and A β 1-42 to a Subset of Senile Plaques", <i>Am. J. Pathology</i> 148(6):1740-1756, 1996.					
Examiner		Date Considered				
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						